Need Help?
Copied to clipboard!

NIBIT-EPI-MESO study samples

Multi-omics analysis of pre-immuno checkpoint inhibitors (ICI) therapy lesions from 91 pleural mesothelioma (PM) patients enrolled in the multicenter NIBIT-EPI-MESO study. Neoplastic lesions were characterized using multiple molecular platforms, including RNA sequencing (n=82), Whole Exome Sequencing (WES) (n=87), Reduced Representation Bisulfite Sequencing (RRBS) (n=83) and cell-free methylated immunoprecipitation sequencing (cfMeDIP-seq) (n=18). Tumor samples were collected during the standard diagnostic pleuroscopy or thoracoscopy before ICI therapy. Matched Peripheral Blood Mononuclear Cells (PBMC) were collected from PM patients before ICI therapy.

Cite

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD50000002126 Illumina NovaSeq X 18
EGAD50000002127 Illumina NovaSeq 6000 42
EGAD50000002128 Illumina NovaSeq 6000 90
EGAD50000002129 Illumina NovaSeq 6000 58
EGAD50000002130 Illumina NovaSeq 6000 25
EGAD50000002131 Illumina NovaSeq 6000 82